Verbatim response from Claude
This is a fast-moving situation, so I want to be straightforward with you:
What Happened
The FDA declared the semaglutide shortage over (early 2025), which banned most compounding pharmacies from making compounded semaglutide. Tirzepatide compounding is also under pressure.
Services That Were Still Navigating This Space (verify current status):
- Hims & Hers - fought back legally and continued briefly, but faced significant restrictions
- Ro - largely shifted to brand-name medications
- Henry - moved toward branded options
- LifeMD - similar transition
Honest Reality Check:
- Most major telehealth platforms have stopped or significantly reduced compounded GLP-1 offerings as of mid-2025
- Some smaller compounding pharmacies may still operate in a gray area
- The legal landscape is actively changing - what's available today may differ next week
What I'd Recommend:
- Check each service's current website directly - policies change weekly
- Ask specifically whether they're offering branded Ozempic/Wegovy/Zepbound instead
- Be cautious of services claiming to still offer compounded versions without clear FDA compliance explanations
Would you like help thinking through the branded medication access options instead, which may be more stable?